Deutsche Bank set a €140.00 ($162.79) price objective on Carl Zeiss Meditec (ETR:AFX) in a report released on Tuesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. Independent Research set a €93.00 ($108.14) price target on Carl Zeiss Meditec and gave the company a sell rating in a report on Tuesday, December 10th. Kepler Capital Markets set a €80.00 ($93.02) price target on Carl Zeiss Meditec and gave the company a sell rating in a report on Monday. Nord/LB set a €132.00 ($153.49) price target on Carl Zeiss Meditec and gave the company a buy rating in a report on Wednesday, December 11th. Hauck & Aufhaeuser set a €110.00 ($127.91) price target on Carl Zeiss Meditec and gave the company a neutral rating in a report on Friday, January 31st. Finally, DZ Bank restated a neutral rating on shares of Carl Zeiss Meditec in a report on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and a consensus target price of €111.14 ($129.24).

Shares of Carl Zeiss Meditec stock opened at €109.50 ($127.33) on Tuesday. The company has a 50-day simple moving average of €115.95 and a two-hundred day simple moving average of €106.71. Carl Zeiss Meditec has a twelve month low of €71.25 ($82.85) and a twelve month high of €122.10 ($141.98). The stock has a market capitalization of $9.79 billion and a price-to-earnings ratio of 61.31. The company has a quick ratio of 3.01, a current ratio of 3.84 and a debt-to-equity ratio of 4.06.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.

Recommended Story: Is it Safe to Invest in Commodities?

Analyst Recommendations for Carl Zeiss Meditec (ETR:AFX)

Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.